Skip to main content

Market Overview

Deutsche Bank Says MedAssets 'Wrestled Into Submission,' Downgrades To Hold


In a report published Tuesday, Deutsche Bank analyst George Hill commented that MedAssets, Inc. (NASDAQ: MDAS) pre-announced fourth quarter results of $0.39 was one penny short of what he expected and the company's 2015 guidance resulted in a negative view of shares.

"Perhaps most unsettling is indications of increased price and margin compression in the core GPO segment, which forces us to question the sustainability of the company's margin structure," Hill wrote. "This instability is more than we can stomach."

Hill added that the poor guidance includes a decreased revenue growth rate, an unfavorable revenue mix weighted towards advisory solutions and a projected incentive comp of $10 million reflecting SCM under-performance in fiscal 2014. The analyst also added that it is not clear if a margin compression will persist on a forward basis.

As a result of the company's guidance, Hall downgraded shares to Hold from Buy with a price target lowered to $19 from a previous $23.

Shares were down more than 12 percent at $17.40.

Latest Ratings for MDAS

Jan 2016SunTrust Robinson HumphreyTerminatesNeutral
Nov 2015JP MorganAssumesNeutral
Nov 2015SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings


Related Articles (MDAS)

View Comments and Join the Discussion!

Posted-In: Deutsche Bank George Hill SCMAnalyst Color Downgrades Price Target Analyst Ratings

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at